TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01239498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of Saline + Lidocaine/Adrenaline
Description: All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The experimental eyelid will receive a saline-consisted injection 0.5cc prior to the administration of the anesthetic injection.~Injection of Saline + Lidocaine 1%
Study: NCT04406285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol Lymphoma
Description: * Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodic Resistance Training Program Lymphoma
Description: * Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels.
Study: NCT01143207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Description: Injectable hormonal contraceptive
Study: NCT03611010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin injection
Description: statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin injection
Description: statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin injection
Description: statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin injection
Description: statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection
Study: NCT02063880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urgent ART
Description: Children will be started on HAART \<48 hours after enrollment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early ART
Description: Children will be started on ART after stabilization 7-14 days after enrollment.
Study: NCT01239498

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine/Adrenaline only
Description: Injection of Lidocaine/Adrenaline only
Study: NCT02806063

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraoperative samples
Study: NCT02835755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive standard HPV and HPV vaccine information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive mHealth HPV vaccine intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03359941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture points: Examples of acupuncture points to be used include BL23 (Sinsu, bilateral), BL24(Gihaesu, bilateral), BL25(Daejangsu, bilateral), BL40(Wijung, bilateral), BL60(Gollyun, bilateral), BL65(Sokgol, bilateral), LI11(Gokji, bilateral), LI4(Hapgok, bilateral), ST36(Joksamni, bilateral), GB41(Jogimeup, bilateral), LR3(Taechung, bilateral). Electrical stimulation with alternating frequency of 2-100 Hz will be applied to the selected points (e.g., BL 23-25, bilateral). Treatments will be provided by qualified Korean traditional medicine doctors with more than 2 years of clinical experience.
Study: NCT02441322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novo-TTF
Description: Procedures: MRI and advanced MRI sequence Advanced brain MRI's with special sequences will be obtained. First MRI prior to starting Novo-TTF therapy, second MRI up to 2-3 weeks after beginning therapy, third MRI up to 2 months from starting treatment and the last MRI up to 4 months after starting treatment.
Study: NCT02834390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: \[Induction period, Cycle 1\] Once-daily repeated oral administration Day 8 to Day 21.~\[Induction period, Cycle 2\] Once-daily repeated oral administration Day 6 to Day 19.~\[Consolidation period\] Once-daily repeated oral administration Day 6 to Day 19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: \[Induction period, Cycle 1\] Once-daily repeated oral administration Day 8 to Day 21.~\[Induction period, Cycle 2\] Once-daily repeated oral administration Day 6 to Day 19.~\[Consolidation period\] Once-daily repeated oral administration Day 6 to Day 19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: \[Induction period, Cycle 1\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 7.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 5.~\[Consolidation period\] Twice-daily intravenous injection of 3.0 g/m\^2 cytarabine at 12-hour intervals on Days 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: \[Induction period, Cycle 1\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 7.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 5.~\[Consolidation period\] Twice-daily intravenous injection of 3.0 g/m\^2 cytarabine at 12-hour intervals on Days 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 and 2.
Study: NCT00939523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: All participants will be asked to take Lapatinib daily for six months during the research study.
Study: NCT02327325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Telephone-based training in multiple skills for managing low back pain.
Study: NCT02966730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered orally, on a once daily continuous dosing schedule and in an outpatient setting. Treatment will continue for 2 years and there will be no planned treatment breaks. The dose of Ibrutinib will be initiated at 560mg per day, which will remain constant throughout the study period, unless otherwise specified.
Study: NCT00658034

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Subjects will receive acupuncture weekly for six weeks. Subjects will complete a Brief Fatigue Inventory (BFI) questionnaire, a Functional Assessment of Cancer Treatment scale (FACT-G), and a Hospital Anxiety and Depression Scale(HADS) at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo Acupuncture
Description: Subjects will receive placebo acupuncture weekly for six weeks. During the placebo phase, placebo acupuncture needles will be applied a few mm away from the required points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. When it is pressed against the skin, the subject feels a slight prick and sees the handle of the needle moving towards the skin as if the needle has been inserted.~Subjects will complete a BFI, a FACT-G, and a HADS at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why. Subjects in the placebo group will be given the option to receive true acupuncture.
Study: NCT04011098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural Fentanyl Bolus
Description: Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Epidural Group
Description: The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
Study: NCT03426540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.
Study: NCT03310593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol as active intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention.
Study: NCT00907205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF1126
Description: Dose Escalating with 3+ patients in each cohort
Study: NCT02421627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral). using mild-warm moxibustion，the surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham moxibustion
Description: Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral); using sham mild-warm moxibustion，the surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
Study: NCT02941523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administration
Study: NCT04449341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Go headset with Ocean Rift application
Description: Information already included in arm description
Study: NCT00027417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liothyronine sodium/triiodothyronine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liothyronine sodium/triiodothyronine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary bypass and cardiac surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiopulmonary bypass and cardiac surgery
Study: NCT02266940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a suspension
Description: DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a tablet
Description: A 200 mg DS 1971a tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a tablet
Description: A 200 mg DS 1971a tablet for oral administration
Study: NCT02413034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cefazolin (vancomycin in the case of allergy to cefazolin)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: no antibiotic prophylaxis
Study: NCT03467737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal sorghum porridge, algal starch
Description: Normal sorghum porridge with 13C-labeled algal starch was fed, breath tested, as the first arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal sorghum porridge, algal dextrins
Description: Normal sorghum porridge with 13C-labeled starch limit dextrins was fed, breath tested, as the second arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal sorghum porridge, labeled flour
Description: Normal sorghum porridge with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified sorghum porridge, labeled flour
Description: Modified sorghum porridge with shear stirring to reduce viscosity with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thinned sorghum porridge, labeled flour
Description: Thinned sorghum porridge treated with an alpha-amylase liquifying enzyme with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified sorghum porridge, octanoic acid
Description: Modified sorghum porridge with shear stirring to reduce viscosity with addition of 13C-labeled octanoic acid was fed, breath tested, for gastric emptying assessment in healthy and moderately malnourished children.
Study: NCT02542371

Intervention type: OTHER
Intervention: Arterial Imaging

Intervention type: OTHER
Intervention: Arterial Imaging

Intervention type: OTHER
Intervention: Arterial Imaging
Study: NCT00696683

Intervention type: OTHER
Intervention: None, this is an observational study
Study: NCT02695875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aquatic therapy
Description: Pool material is contributed by Maria José Jove Foundation. The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Land-based therapy
Description: The material is contributed by Faculty of Physiotherapy at University of A Coruña.~The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance.
Study: NCT02647840

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: voice therapy
Description: voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
Study: NCT03816579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO-A
Description: 30 g of beef protein will be consumed at each meal
Study: NCT03803267

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: For each side, the eighth thoracic transverse process will be identified by a linear US transducer (HFL38_10-5 MHz), puncture will be performed in the plane in the craniocaudal direction until the needle contacts the transverse process, and 20 ml of bupivacaine 0.25% and 4 mg dexamethasone will be injected visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesirable motor weakness will be recorded as a side effect.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: For each side, shamrock sign with three leaves (psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process of the L4 vertebral body) will be identified by a curved array US transducer (6-2MHz), puncture will be performed in-plane, the needle will be advanced through the quadratus lumborum muscle penetrating the ventral proper fascia of the quadratus lumborum muscle, and 20 mL of bupivacaine 0.25% and 4 mg dexamethasone will be injected in that space visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesired motor weakness will be recorded as a side effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (2 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (2 mg/kg)
Study: NCT04343729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Sodium Succinate
Description: injectable solution at a dose of 0.5mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: injectable saline solution
Study: NCT02338037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo tumor resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: Undergo intracerebral microdialysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04669613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CUDI
Description: Analysis of the CEUS data by means of Contrast ultrasound dispersion imaging
Study: NCT02400190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endocrine therapy alone without radiotherapy
Description: Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
Study: NCT00753987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: 5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
Study: NCT03673202

Intervention type: DIAGNOSTIC_TEST
Intervention: Cx bladder Monitor test
Description: Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).
Study: NCT04484064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence program
Description: This program combines adherence evaluation using an electronic monitor (MEMS®) and feedback with repeated medication adherence interviews with the pharmacist.
Study: NCT03109717

Intervention type: DRUG
Intervention: Monoamine Oxidase Inhibitor (MAOI)
Description: Monoamine Oxidase Inhibitor
Study: NCT03597321

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prophylactic donor lymphocyte infusion (DLI)
Description: DLI will be collected from the donor by leukapheresis according to local standard procedures of each center. Cell product could be collected in one time or more, and administered fresh or after a frozen storage, according to each center's guidelines. A sufficient amount of T-cell dose should be collected to theoretically perform 3 DLI. DLI procedure will be performed according to local guidelines of each center.
Study: NCT04483544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: PD-1 inhibitor pembrolizumab, 200mg intravenously (IV) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: PARP inhibitor olaparib 300 mg orally, twice daily (BID)
Study: NCT02144324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem Appliance
Description: We are going to use a modified version of the Tandem Appliance